Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 10/20 | 0.56 |
| ▸ | MAOB | P27338 | 10/20 | 0.56 |
| ▸ | PRKCI | P41743 | 1/20 | 0.56 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.50 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | GRM5 | P41594 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | PGR | P06401 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | CASP7 | P55210 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MIF | P14174 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1856486 | 0.89 | HSD17B10 (0.53) | MAOAMAOBPRKCIHSD17B1BAZ2B | |
| SCHEMBL23789055 | 0.86 | MAOA (0.53) | MAOAMAOBPRKCIHSD17B1BAZ2B | |
| SCHEMBL1401942 | 0.86 | MAOA (0.48) | MAOAMAOBPRKCIHSD17B1BAZ2B | |
| SCHEMBL21659213 | 0.83 | MAOA (0.50) | MAOAMAOBPRKCIHSD17B1BAZ2B | |
| SCHEMBL27844102 | 0.82 | KDM4E (0.42) | MAOAMAOBPRKCIHSD17B1BAZ2B | |
| SCHEMBL27843782 | 0.82 | KDM4E (0.42) | MAOAMAOBPRKCIHSD17B1BAZ2B | |
| SCHEMBL14849265 | 0.82 | HPGD (0.46) | MAOAMAOBPRKCIBAZ2BCYP2A6 | |
| SCHEMBL25700399 | 0.81 | KDM4E (0.38) | MAOAMAOBPRKCIHSD17B1BAZ2B | |
| SCHEMBL20055113 | 0.78 | LMNA (0.52) | MAOAMAOBKDM4EMEN1KMT2A | |
| SCHEMBL25795405 | 0.77 | PARP11 (0.51) | GRM5HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230286991-A1 | 7-(PIPERIDIN-1-YL)-4H-PYRIMIDO[1,2-B]PYRIDAZIN-4-ONE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY | 2023-09-14 | — | — | US | disclosed |
| US-20230257381-A1 | 7-(PIPERIDIN-1-YL)-4H-PYRIMIDO[1,2-B]PYRIDAZIN-4-ONE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY | 2023-08-17 | — | — | US | disclosed |
| US-11541126-B1 | Anti-ASGR1 antibody TLR8 agonist comprising conjugates and uses thereof | SILVERBACK THERAPEUTICS, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| EP-3949969-A2 | BENZAZEPINE COMPOUNDS, CONJUGATES, AND USES THEREOF | Silverback Therapeutics, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| US-20200113912-A1 | Methods and Compositions for the Treatment of Disease with Immune Stimulatory Conjugates | SILVERBACK THERAPEUTICS, INC. (US) | 2020-04-16 | — | — | US | disclosed |
| US-20200031798-A1 | BENZAZEPINE COMPOUNDS, CONJUGATES, AND USES THEREOF | ARS Pharmaceuticals, Inc. | 2020-01-30 | — | — | US | disclosed |
| US-10442790-B2 | Benzazepine compounds, conjugates, and uses thereof | SILVERBACK THERAPEUTICS, INC. (US) | 2019-10-15 | — | — | US | disclosed |
| US-10428045-B2 | Benzazepine compounds, conjugates, and uses thereof | SILVERBACK THERAPEUTICS, INC. (US) | 2019-10-01 | — | — | US | disclosed |
| US-20190169164-A1 | BENZAZEPINE COMPOUNDS, CONJUGATES, AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. | 2019-06-06 | — | — | US | disclosed |
| US-10239862-B2 | Benzazepine compounds, conjugates, and uses thereof | SILVERBACK THERAPEUTICS, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-9266892-B2 | Fused pyrazoles as FGFR inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2016-02-23 | — | — | US | disclosed |
| US-20140171405-A1 | Fused Pyrazoles as FGFR Inhibitors | INCYTE CORPORATION (US) | 2014-06-19 | — | — | US | disclosed |
| US-8436016-B2 | Fused heterocyclic M1 receptor positive allosteric modulators | Merck, Sharp & Dohme, Corp. | 2013-05-07 | — | — | US | disclosed |
| US-20110201607-A1 | FUSED HETEROCYCLIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | Merck, Sharp & Dohme, Corp. | 2011-08-18 | — | — | US | disclosed |
| US-7572915-B2 | 4-[(3-methylphenyl)amino]-6-(methylsulfonyl)-3-quinolinecarboxamide; asthma, COPD, allergic rhinitis, or rheumatoid arthritis in a human | GLAXO GROUP LIMITED (GB) | 2009-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140171405-A1 | Fused Pyrazoles as FGFR Inhibitors | FGFR1, FGFR3, FGFR2 | MAOA 4191/4885MAOB 3783/4885PRKCI 1488/4885 |
| US-20200113912-A1 | Methods and Compositions for the Treatment of Disease with Immune Stimulatory Conjugates | CD74, CD47, CD69 | MAOA 2680/4885MAOB 1739/4885PRKCI 2555/4885 |
| US-20190169164-A1 | BENZAZEPINE COMPOUNDS, CONJUGATES, AND USES THEREOF | TLR8, TLR3, TLR5 | MAOA 1690/4885MAOB 1537/4885PRKCI 3180/4885 |
| US-20110201607-A1 | FUSED HETEROCYCLIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | CHRM1, OPRL1, OPRM1 | MAOA 722/4885MAOB 993/4885PRKCI 2170/4885 |
| US-20230286991-A1 | 7-(PIPERIDIN-1-YL)-4H-PYRIMIDO[1,2-B]PYRIDAZIN-4-ONE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | CHRM4, CHRM3, CHRM5 | MAOA 323/4885MAOB 306/4885PRKCI 1944/4885 |
| US-10239862-B2 | Benzazepine compounds, conjugates, and uses thereof | TLR8, TLR3, TLR5 | MAOA 1690/4885MAOB 1537/4885PRKCI 3180/4885 |
| US-10442790-B2 | Benzazepine compounds, conjugates, and uses thereof | TLR8, TLR3, TLR5 | MAOA 1690/4885MAOB 1537/4885PRKCI 3180/4885 |
| US-10428045-B2 | Benzazepine compounds, conjugates, and uses thereof | TLR8, TLR3, TLR5 | MAOA 1690/4885MAOB 1537/4885PRKCI 3180/4885 |
| US-20200031798-A1 | BENZAZEPINE COMPOUNDS, CONJUGATES, AND USES THEREOF | TLR8, TLR3, TLR5 | MAOA 1690/4885MAOB 1537/4885PRKCI 3180/4885 |
| US-20230257381-A1 | 7-(PIPERIDIN-1-YL)-4H-PYRIMIDO[1,2-B]PYRIDAZIN-4-ONE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | CHRM4, CHRM1, CHRM5 | MAOA 254/4885MAOB 226/4885PRKCI 2238/4885 |
| US-11541126-B1 | Anti-ASGR1 antibody TLR8 agonist comprising conjugates and uses thereof | ASGR1, TLR8, HAVCR2 | MAOA 4323/4885MAOB 4577/4885PRKCI 2037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.